Drug Profile


Alternative Names: BAY-86-8050

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Acetamides; Carbamates; Chlorophenols; Fluorocarbons; Heart failure therapies; Small molecules; Triazoles
  • Mechanism of Action Vasopressin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Heart failure

Most Recent Events

  • 02 Sep 2016 Ribuvaptan is still in phase I development in Germany
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Heart-failure in Germany
  • 31 Dec 2011 Phase-I clinical trials in Heart failure in Germany (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top